Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.

dpoints to prove efficacy, which saves time.[ 135 ] Another innovative option is to harmonize regulation between countries, so companies only have to prove efficacy once.[ 135 ] However, because drugs are not necessarily priced based on investment costs, the effects of this approach on drug pricing might not be significant, or as we will see, harmonized regulations may actually be counterproductive.

also in 673 other papers